capuramycin

from Streptomyces griseus 446-S3; structure given in first source

Also Known As:

beta-D-Allofuranuronamide, 1-deoxy-5-O-(4-deoxy-N-(hexahydro-2-oxo-1H-azepin-3-yl)-alpha-L-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-O-methyl-, (S)-

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - capuramycin: 7

Experts

1.	Kurosu, Michio: 2 articles (10/2020 - 10/2013)
2.	Bogatcheva, Elena: 2 articles (05/2016 - 07/2009)
3.	Einck, Leo: 2 articles (05/2016 - 07/2009)
4.	Protopopova, Marina: 2 articles (05/2016 - 07/2009)
5.	Muramatsu, Yasunori: 2 articles (10/2004 - 03/2003)
6.	Chen, Zixi: 1 article (02/2021)
7.	He, Haiqing: 1 article (02/2021)
8.	Huang, Yingying: 1 article (02/2021)
9.	Li, Penghua: 1 article (02/2021)
10.	Sun, Roujing: 1 article (02/2021)

Related Diseases

1.	Tuberculosis (Tuberculoses) 10/04/2013 - "Capuramycin and its congeners are considered to be important lead molecules for the development of a new drug for multidrug-resistant (MDR) Mycobacterium tuberculosis infections. " 07/01/2009 - "Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis." 10/01/2004 - "tuberculosis for any of the capuramycin analogues tested. " 02/23/2021 - "In particular, the current one-pot glycosylation strategy is successfully applied to the total synthesis of a promising tuberculosis drug lead capuramycin and the divergent and formal synthesis of TMG-chitotriomycin with potent and specific inhibition activities toward β-N-acetylglucosaminidases and important endosymbiotic lipochitooligosaccharides including the Nod factor and the Myc factor, which represents one of the most efficient and straightforward synthetic routes toward these biologically salient molecules." 03/01/2003 - "As a single intravenous injection of A-500359 A at a dose of 500 mg/kg showed no toxicity in mice, it was suggested that the capuramycin derivatives might become candidates as novel therapeutic agents for various diseases caused by Mycobacteria including tuberculosis."
2.	Neoplasms (Cancer) 10/08/2020 - "DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors." 10/08/2020 - "In our program of development of new N-acetylglucosaminephosphotransferase1 (DPAGT1) inhibitors, we have identified that a capuramycin phenoxypiperidinylbenzylamide analogue (CPPB) inhibits DPAGT1 enzyme with an IC50 value of 200 nM. Despite a strong DPAGT1 inhibitory activity, CPPB does not show cytotoxicity against normal cells and a series of cancer cell lines. "
3.	Clostridium Infections 05/01/2016 - "Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model."

Related Drugs and Biologics

1.	Enzymes
2.	TMG-chitotriomycin
3.	A-500359 A

Related Therapies and Procedures

1.	Intravenous Injections